MedPath
HSA Product

OXYNORM® Oral Solution 1mg/ml

Product approved by Health Sciences Authority (SG)

Basic Information

OXYNORM® Oral Solution 1mg/ml

SOLUTION

Regulatory Information

SIN14125P

March 28, 2012

Prescription Only

Therapeutic

ORAL

August 10, 2023

May 30, 2025

XN02AA05

Company Information

MUNDIPHARMA PHARMACEUTICALS PTE. LTD.

MUNDIPHARMA PHARMACEUTICALS PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**Contraindications** Hypersensitivity to oxycodone or to any of the excipients listed in section _‘Pharmaceutical Particulars’_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Oxycodone must not be used in any situation where opioids are contraindicated: severe respiratory depression with hypoxia, cor pulmonale, acute abdomen, severe chronic obstructive lung disease, cor pulmonale, elevated carbon dioxide levels in the blood, cardiac arrhythmias, severe bronchial asthma, chronic bronchial asthma or other chronic obstructive airways disease, elevated carbon dioxide levels in the blood, paralytic ileus, suspected surgical abdomen, moderate to severe hepatic impairment, severe renal impairment (creatinine clearance < 10 mL/min), delayed gastric emptying, acute alcoholism, brain tumor, increased cerebrospinal or intracranial pressure, head injury, severe CNS depression, convulsive disorders, delirium tremens, hypercarbia, chronic constipation, concurrent administration of monoamine oxidase inhibitors or within 2 weeks of discontinuation of their use. Not recommended for pre-operative use.

Indication Information

**Therapeutic Indication** The management of acute exacerbation of moderate to severe chronic pain unresponsive to non-narcotic analgesia, and post-operative pain.

© Copyright 2025. All Rights Reserved by MedPath